acinetobacter

Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment.

SPR206 is a polymyxin analogue and an important class of antibiotic for the treatment of bacterial infections due to multidrug resistant Gram-negative pathogen.

BAL30072 shows MIC90 values of 4 μg/mL for MDR Acinetobacter spp. and 8 μg/mL for MDR P. aeruginosa, respectively[1][2]. BAL-30072, a siderophore sulfactam, is a monocyclic beta-lactam antibiotic, with activity against multiresistant gram-negative bacilli

SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate efficiently combats bacterial infections, displaying significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against [Pseudomonas aeruginosa Pa14] and [Acinetobacter baumannii NCTC13301].

Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic derived from tetracycline that binds to the 30S ribosomal subunit, disrupting the binding of aminoacyl-tRNA to the mRNA-ribosome complex.

N-phenylacetyl-L-Homoserine lactone attenuates the group sensing of the pathogen Acinetobacter baumannii and can be used to study bacterial infections.

Cerastecin D (compound 1), an antibacterial agent, demonstrates effectiveness by inhibiting Acinetobacter baumannii ATCC19606 with MITC 95 values at 165 nM.

P6P-10,10, an antimicrobial agent, exhibits an IC50 of 3 μM against colistin-resistant Acinetobacter baumannii.

MLEB-22043 is a synthetic siderophore-monocyclic β-lactam conjugate which enters bacteria through TonB-dependent transport proteins utilizing its siderophore component, subsequently exerting antibacterial activity via its β-lactam portion. This compound acts as a broad-spectrum antibiotic, exhibiting significant inhibitory activity against pathogens such as Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Debio-1452-NH3 is a novel and potent FabI antibody—enoyl-acyl carrier protein reductase inhibitor that demonstrates excellent efficacy in reducing bacterial load in mice. It effectively treats lethal infections caused by clinically isolated strains of Pseudomonas aeruginosa (Acinetobacter baumannii), Klebsiella pneumoniae, and Escherichia coli (E. coli).

DNA Gyrase-IN-15 (Compound 11) is an antibacterial agent that inhibits both DHPS and DNA gyrase, with IC50 values of 1.73 and 0.07 µM, respectively. It shows antimicrobial activity against Enterococcus faecium (MIC of 15.62 µg/mL), Acinetobacter baumannii, Enterobacter (MIC of 7.81 µg/mL), Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus. Additionally, DNA Gyrase-IN-15 exhibits antibiofilm activity against Enterococcus faecium.

Antibacterialagent 274 (Compound 18b) is an antibacterial agent that targets bacterial cell membranes, exhibiting a minimum inhibitory concentration (MIC) of 8 μg/mL against Acinetobacter baumannii ATCC 17978. It functions by disrupting membrane integrity, causing intracellular accumulation of ROS, which leads to DNA and protein leakage, thereby exerting its antibacterial effects. Antibacterialagent 274 is applicable in research on infections caused by Gram-negative bacteria.

Zosurabalpin TFA is a macrocyclic peptide antibiotic that specifically targets Acinetobacter baumannii (A. baumannii) by inhibiting lipopolysaccharide transport.

IITR08367 is a potent inhibitor of the efflux pump Acinetobacter baumannii Fosfomycin Efflux pump (AbaF), designed to enhance the antibacterial activity of Fosfomycin against Acinetobacter baumannii. It operates by disrupting the Fosfomycin/H+ antiport activity.

Apalcillin (PC-904) combined with Ro 48-1220 (a penicillin sulfone β-lactamase inhibitor) exhibits broad-spectrum activity against Gram-negative aerobic and anaerobic bacteria, excluding Klebsiella acid-producing strains. This combination shows strong efficacy against β-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae, and Neisseria gonorrhoeae with an effective MIC of 11 μg/mL. Additionally, it inhibits Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter at low MICs (0.25 to 4 μg/mL). However, it has limited efficacy against oxacillin-resistant staphylococci and some Gram-positive bacteria. Apalcillin/Ro 48-1220's effectiveness against certain extended-spectrum β-lactamase-producing Escherichia coli is comparable to piperacillin/tazobactam, though it is less effective against SHV-type β-lactamases.

Antibacterialagent 285 (Compound 3) is a cephalosporin antibiotic. It exhibits significant antibacterial activity against Gram-negative bacteria, with minimum inhibitory concentrations (MIC) of 0.125-0.5 μg/mL for carbapenem-resistant Acinetobacter baumannii (CRAB), 0.125-0.5 μg/mL for Klebsiella pneumoniae (CRE), and 0.125-2 μg/mL for Pseudomonas aeruginosa (CRPA). Antibacterialagent 285 can be utilized in bacterial infection research, including studies on complicated urinary tract infections (cUTI) and kidney infections.

CYP1A1-IN-1 (Compound 47) is a small molecule inhibitor of cytochrome P450 1A1 (CYP1A1). It reduces the bacterial load of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii by enhancing macrophage phagocytosis. CYP1A1-IN-1 shows potential for research in sepsis caused by multi-drug resistant (MDR) bacteria.

ANT3310 is a broad-spectrum covalent inhibitor of serine β-lactamase (Serine β-Lactamase) with an IC50 range of 1 nM to 175 nM against various serine β-lactamases. ANT3310 enhances the efficacy of β-lactam antibiotics against carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB). It is applicable for studies related to bacterial infections.

Sarecycline hydrochloride (Sarecycline HCl) is an orally active narrow-spectrum tetracycline antibiotic with antimicrobial and anti-inflammatory activity, inhibits Acinetobacter and Candida tropicalis, and can be used to treat inflammatory acne.

DS86760016 is a highly effective inhibitor of leucyl-tRNA synthetase (LeuRS), demonstrating potent activity against multidrug-resistant (MDR) Gram-negative bacteria including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Notably, DS86760016 effectively inhibits LeuRS enzymes derived from Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, exhibiting IC50 values of 0.38 μM, 0.62 μM, and 0.16 μM, respectively.

APO-6619 is an iron chelator which was shown to inhibit growth of the following bacterial strains: Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. APO-6619 may be useful as a non-traditional treatment of bacterial infections.

Colistin (Polymyxin E), a polypeptide antibiotic with oral activity, exhibits strong efficacy against a range of Gram-negative rod-shaped bacteria, such as multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. However, its use is associated with nephrotoxicity. It is primarily utilized in researching infections caused by Gram-negative bacilli [1] [2].

The compound demonstrates enhanced potency against wild-type (WT) strains of Escherichia coli, Acinetobacter baumannii, and Burkholderia cenocepacia, showing significant improvements of up to (>128-fold) due to increased outer-membrane permeability in hyperpermeable E. coli strains and S. Tm.

Zosurabalpin (Abx MCP) is a macrolide antibiotic effective against drug-resistant Gram-negative bacteria, such as carbapenem-resistant Acinetobacter baumannii (CRAB), by binding to and inhibiting the protein machinery complex LptB2FGC involved in the transport of outer membrane lipopolysaccharides.